2016 経営基本計画（16CSP）参考資料

2016 経営基本計画（16CSP）参考資料
経営⽬標
FY2012
ROE
営業利益率
EBITDA（億円）　※1
⾃⼰資本⽐率
FY2013
FY2014
FY2015
FY2016
⾒通し
~
FY2021
経営⽬標
FY2017~FY2021
CAGR
-62.3%
8.3%
5.7%
-2.6%
約15%
15%
4.2%
4.7%
10.3%
11.9%
約12%
15%
804
787
1,198
1,416
約1,500
2,400
4.6%
15.5%
32.1%
32.9%
約39%
50%
10%
主要経営指標等
FY2012
売上⾼（億円）
営業利益（億円）
当期純利益（億円）　※2
総資産（億円）
純資産（億円）
⾃⼰資本（億円）
1株当たり当期純利益⾦額（円）　※2
1株当たり純資産額（円）
1株当たり配当額（円）
連結総還元性向
売上⾼純利益率
総資産回転率（回）
財務レバレッジ（倍）
FY2013
FY2014
FY2015
FY2016
⾒通し
8,160
1,000
560
8,485
355
-490
9,665
480
448
-184
168
-5.8%
0.9
21.6
7,439
351
80
9,602
1,519
1,486
29
493
1.1%
0.8
6.5
7,133
734
136
10,275
3,313
3,295
41
963
1.9%
0.7
3.1
7,647
910
-87
10,816
3,573
3,555
-26
1,039
10
-1.1%
0.7
3.0
研究開発費（億円）
614
634
668
741
800
設備投資額（億円）
380
281
378
477
690
減価償却費（億円）
のれん償却（億円）
338
111
339
97
369
95
412
94
430
92
フリーキャッシュ・フロー（億円）
-48
587
521
272
~
FY2021
⾒通し
11,000
1,700
1,100
163
FY2017~FY2021
CAGR
6%
11%
15%
320
17
10%
7%
30%
10%
0.9
2.0
5年間累計
4,300〜4,800
5年間累計
3,000〜3,500
700
700
5年間累計
2,500以上
為替（期中平均レート）
FY2012
USD（円）
EUR（円）
79.08
108.98
FY2013
83.10
107.14
FY2014
100.24
134.37
FY2015
109.93
138.77
FY2016
⾒通し
120.00
133.00
~
FY2021
⾒通し
115.00
130.00
主要セグメント数値
FY2012
売上⾼（億円）
医療
科学
映像　※3
情報通信
その他　※3
全社・消去
営業利益（億円）
医療
科学
映像　※3
情報通信
その他　※3
全社･消去
営業利益率
医療
科学
映像　※3
情報通信
その他　※3
全社･消去
8,485
3,492
924
1,286
2,294
489
355
682
54
-108
53
-80
-246
4.2%
19.5%
5.9%
2.3%
-
FY2013
7,439
3,947
855
1,076
1,142
417
351
871
35
-231
17
-49
-293
4.7%
22.1%
4.1%
1.5%
-
FY2014
7,133
4,923
985
961
264
734
1,127
49
-92
-54
-297
10.3%
22.9%
5.0%
-
FY2015
7,647
5,583
1,039
794
230
910
1,249
68
-117
-10
-281
11.9%
22.4%
6.6%
-
FY2016
⾒通し
8,160
6,150
1,060
800
150
1,000
1,370
80
0
-120
-330
12.3%
22.3%
7.5%
0.0%
-
~
FY2021
⾒通し
11,000
9,000
1,300
550
150
1,700
2,250
130
20
-700
-700
※1　EBITDA＝営業利益＋減価償却費＋のれん償却費
※2　ここでの「当期純利益」は「親会社株主に帰属する当期純利益」を指します
※3　2015年4⽉より従来「映像事業」に区分されていた新規事業を「その他事業」に変更したため、2015年3⽉期を区分変更後の情報
で記載しています
15%
25%
10%
4%
-
FY2017~FY2021
CAGR
6%
8%
4%
-7%
0%
11%
10%
10%
-
Financial data for 2016 Corporate strategic plan
Corporate Management Targets
FY2012
Return on equity(ROE)
Operating margin
EBITDA [Billions of yen]　*1
Equity ratio
FY2013
FY2014
FY2015
-62.3%
8.3%
5.7%
-2.6%
4.2%
4.7%
10.3%
11.9%
80.4
78.7
119.8
141.6
4.6%
15.5%
32.1%
32.9%
FY2017~FY2021
CAGR
FY2016
…
forecast
approx.
15%
approx.
12%
approx.
150.0
approx.
39%
FY2021
target
FY2016
…
forecast
816.0
FY2021
forecast
1,100.0
FY2017~FY2021
CAGR
6%
15%
15%
240.0
10%
50%
Corporate Management Indicators
FY2012
FY2013
FY2014
FY2015
Net sales [Billions of yen]
Operating income [Billions of yen
848.5
743.9
713.3
764.7
35.5
35.1
73.4
91.0
100.0
170.0
11%
Net income [Billions of yen] *2
-49.0
8.0
13.6
-8.7
56.0
110.0
15%
Total assets [Billions of yen]
Total net assets [Billions of yen]
966.5
48.0
960.2
151.9
1,027.5
331.3
1,081.6
357.3
44.8
-184
148.6
29
329.5
41
355.5
-26
163
320
168
493
963
1,039
-
-
-
10
-
17
10%
30%
-5.8%
0.9
1.1%
0.8
1.9%
0.7
-1.1%
0.7
7%
21.6
6.5
3.1
3.0
61.4
63.4
66.8
74.1
80.0
38.0
28.1
37.8
47.7
69.0
33.8
33.9
36.9
41.2
43.0
11.1
9.7
9.5
9.4
9.2
-4.8
58.7
52.1
27.2
Equity [Billions of yen]
Net income per share [Yen] *2
Total equity per share [Yen]
Cash dividends per share [Yen]
Consolidated total return ratio
Net income magin
Total asset turnover [times]
Financial leverage [times]
R&D expenditures
[Billions of yen]
Capital expenditures
[Billions of yen]
Depreciation and amortization
[Billions of yen]
Amortization of goodwill
[Billions of yen]
Free cash flow [Billions of yen]
10%
0.9
2.0
FY2017~FY2021
Total 430.0~480.0
FY2017~FY2021
Total 300.0~350.0
70
70.0
FY2017~FY2021
Total 250.0
and over
Average exchange rate
FY2012
Yen / U.S. dollar
Yen / Euro
79.08
108.98
FY2013
83.10
107.14
FY2014
100.24
134.37
FY2015
109.93
138.77
FY2016
…
forecast
120.00
133.00
FY2021
forecast
115.00
130.00
FY2016
…
forecast
816.0
615.0
106.0
80.0
15.0
100.0
137.0
8.0
0.0
-12.0
-33.0
12.3%
22.3%
7.5%
0.0%
-
FY2021
forecast
1,100.0
900.0
130.0
55.0
15.0
170.0
225.0
13.0
2.0
-70.0
-70.0
Net sales and operating income by business segment
FY2012
Net sales [Billions of yen]
Medical
Scientific Solutions
Imaging *3
Information & Communication
Others *3
Elimination or Corporate
Operating income [Billions of yen]
Medical
Scientific Solutions
Imaging *3
Information & Communication
Others *3
Elimination or Corporate
Operating margin (consolidated)
Medical
Scientific Solutions
Imaging *3
Information & Communication
Others *3
Elimination or Corporate
848.5
349.2
92.4
128.6
229.4
48.9
35.5
68.2
5.4
-10.8
5.3
-8.0
-24.6
4.2%
19.5%
5.9%
2.3%
-
FY2013
743.9
394.7
85.5
107.6
114.2
41.7
35.1
87.1
3.5
-23.1
1.7
-4.9
-29.3
4.7%
22.1%
4.1%
1.5%
-
FY2014
713.3
492.3
98.5
96.1
26.4
73.4
112.7
4.9
-9.2
-5.4
-29.7
10.3%
22.9%
5.0%
-
FY2015
764.7
558.3
103.9
79.4
23.0
91.0
124.9
6.8
-11.7
-1.0
-28.1
11.9%
22.4%
6.6%
-
FY2017~FY2021
CAGR
6%
8%
4%
-7%
0%
11%
10%
10%
-
15%
25%
10%
4%
-
*1　EBITDA＝Operating income + Depreciation and amortization + Amortization of goodwill
*2　This "net income" means "net income attributable to owners of the parent"
*3　From April 1, 2015, the new business previously included in "Imaging" is included in "Others", so the ﬁnancial data of FY2015
is corrected to new segmentation
-

Download Report